fluticasone

(redirected from Breo Ellipta)
Also found in: Dictionary, Wikipedia.
Related to Breo Ellipta: Advair

fluticasone

 [floo-tik´ah-sōn″]
a steroid antiinflammatory agent, used as the propionate salt topically in treatment of itching or inflammation, intranasally for allergic rhinitis and other inflammatory nasal conditions, and nasal polyps, and by inhalation in treatment of asthma.

fluticasone

/flu·tic·a·sone/ (floo-tik´ah-sōn″) a synthetic corticosteroid used as the propionate salt to treat inflammation in certain dermatoses, allergic rhinitis and other inflammatory nasal conditions, nasal polyps, and asthma.

fluticasone

[floo͡tik′äsōn′]
a steroid antiinflammatory agent, used topically as the propionate salt in treatment of itching or inflammation, intranasally in the treatment of allergic rhinitis and other inflammatory nasal conditions and of nasal polyps, and by inhalation in treatment of asthma.

fluticasone

A CORTICOSTEROID drug used as an inhalant to treat ASTHMA and hay fever. Extensive studies have shown that fluticasone is safe and effective and, in the recommended dosage, does not affect growth in childhood. Brand names are Flixonase (nasal spray), Flixotide (inhaler) and, for external use only, Cutivate. With SALMETEROL it is marketed as Seretide.
References in periodicals archive ?
Breo Ellipta is our second asthma treatment to be approved in the US in the past year, and now provides physicians with a range of treatment options delivered via the Ellipta inhaler to meet the needs of appropriate adult patients with differing asthma severities.
said: "We believe the approval of Breo Ellipta as a once-daily ICS/LABA treatment for adults with asthma is a significant catalyst for Theravance, as asthma affects nearly 19 million adults in the US.
Both Breo Ellipta and vilanterol, a long-acting beta2-adrenergic agonist (LABA), is crucial for Theravance.
Breo Ellipta, a blend of fluticasone furoate, is an inhaled corticosteroid.
BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate FF , and the long-acting beta2 agonist (LABA), vilanterol VI (FF/VI 100/25 mcg).
BREO ELLIPTA , is the proposed proprietary name for FF/VI 100/25 mcg, a combination of the inhaled corticosteroid (ICS) fluticasone furoate FF and the long acting bronchodilator (LABA) vilanterol VI (FF/VI).
BREO ELLIPTA is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
Breo Ellipta is expected to be available from the third/fourth quarter of 2013.
Rick E Winningham, Theravance's Chief Executive Officer, said, "In the second half of 2013, we anticipate a number of significant events: the launch of BREO ELLIPTA in the U.
We note that Glaxo's product portfolio was boosted recently with the approvals of two melanoma drugs, Tafinlar (dabrafenib) and Mekinist (trametinib) and chronic obstructive pulmonary disease drug, Breo Ellipta.
Darrell Baker, SVP & Head, GSK Global Respiratory Franchise, said, "This approval means that we can now realise our plan to bring BREO ELLIPTA to appropriate COPD patients in the US.
The panel's positive recommendation of BREO ELLIPTA represents an important achievement in a transformative year for Theravance.